The Elsevier Publishing Group annually recognizes excellence and commitment of public and private institutions for the benefit of research and health. The prestigious award was presented at a ceremony chaired by the Spanish Minister of Health, Bernat Soria.

"Our contribution to cancer therapies has materialized with the commercialization of Yondelis," said Luis Mora, general manager of PharmaMar, during his speech Madrid, October 23, 2008: PharmaMar, a biotechnology company of Zeltia Group, was honoured yesterday by Elsevier Galien for "Excellence in R & D and innovation in Biotechnology", one of the prizes that Elsevier Publishing Group awards in recognition of excellence and commitment of public and private institutions for the benefit of research and health.

The general manager of PharmaMar (Zeltia Group), Luis Mora, collected the award. During his speech he thanked Elsevier Galien for the award and said it represented a push to continue "with this exciting journey of discovery, research and development of new drugs with the mission for improving health and quality of life in our society." "Our contribution to cancer therapies have materialized with the commercialization of Yondelis, the first medicine of marine origin researched, developed and commercialized by a Spanish Biotech company," said Luis Mora during his speech.

The Awards Ceremony was chaired by Bernat Soria, the Spanish Health Minister. Elsevier Galien Awards were created in France in 1970 by joint initiative of Le Quotidien du Médecin and Le Quotidien du Pharmacia. Its International Honour Committee brings together, mong other members,two Nobel Prizes in Medicine; teachers Jean Dausset and François Jacob, and Professor Michael Smith, Nobel Laureate in Chemistry.

PharmaMar is the world-leading biopharmaceutical company of the Zeltia Group, and is committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines.